Work

389P Efficacy and safety analyses by prior lines of chemotherapy from the phase III TROPiCS-02 study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with HR+/HER2- metastatic breast cancer (mBC)

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.09.566

Authors: J. Cortés, F. Marmé, P. Schmid, H.S. Rugo, S.M. Tolaney, W. Verret, T. Valdez, Y. Huo, A. Bardia

Institutions: University Medical Centre Mannheim, Barts Health NHS Trust, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, Harvard University, Gilead Sciences (United States), Massachusetts General Hospital

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: AstraZeneca, Gilead Sciences, Daiichi Sankyo Europe

OpenAlex ID: W4387808529

FWCI: 0.354

Cites:

Cited by: 2

Related to: 10